

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/14801

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K51/04 G01N33/94

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/21219 A (ANDERSON LAWRENCE ; KLECKER RAYMOND N (US); US HEALTH (US); COLLINS JE) 29 March 2001 (2001-03-29) claims 1,3,7	1,12-14
X	SLATTER, JOHN GREG ET AL: "Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of ¹⁴ C!CPT-11 in cancer patients" DRUG METABOLISM AND DISPOSITION , 28(4), 423-433 CODEN: DMDSAI; ISSN: 0090-9556, 2000, XP002278174 figure 1	1-7, 12-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the International search

6 May 2004

Date of mailing of the International search report

17/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/14801

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ATSUMI R ET AL: "Pharmacokinetics of SN-38 '(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione!, an active metabolite of irinotecan, after a single intravenous dosing of ¹⁴C-SN-38 to rats." BIOLOGICAL & PHARMACEUTICAL BULLETIN. AUG 1995, vol. 18, no. 8, August 1995 (1995-08), pages 1114-1119, XP0001189416 ISSN: 0918-6158 abstract</p>	1-7, 12-14
X	<p>HINZ H R ET AL: "Stabilities of <3>H- and <2>H-labelled camptothecins" JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS 1996 UNITED KINGDOM, vol. 38, no. 8, 1996, pages 733-742, XP0008030200 ISSN: 0362-4803 abstract</p>	1-7, 12-14
X	<p>RONMAN P E ET AL: "THE PREPARATION OF TRITIUM LABELED CAMPTOTHECIN AND DEUTERIUM LABELED CAMPTOTHECIN" JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 18, no. 3, 1981, pages 319-330, XP0008030202 & ISSN: 0362-4803 abstract</p>	1-7, 12-14
X	<p>EMERSON D L ET AL: "Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUL 2000, vol. 6, no. 7, July 2000 (2000-07), pages 2903-2912, XP002279091 ISSN: 1078-0432 abstract</p>	1-7, 12-14
A	<p>GABR A ET AL: "Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH." CANCER RESEARCH. 1 NOV 1997, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4811-4816, XP001189417 ISSN: 0008-5472 page 4812, column 1, paragraph 2</p>	1-14

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/14801

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NICHOLAS ALLAN W ET AL: "Synthesis of position-specific tritium-labeled 20(S)-camptothecin, 9-amino-20(S)-camptothecin, and 10,11-methylenedioxy-20(S)-camptothecin" JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 33, no. 9, 1993, pages 839-848, XP008030201 & ISSN: 0362-4803 abstract</p> <p>-----</p>	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/14801

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0121219	A	29-03-2001	AU	7597000 A	24-04-2001
			WO	0121219 A2	29-03-2001